Literature DB >> 15160809

Quality incentives: the case of U.K. general practitioners.

Peter C Smith1, Nick York.   

Abstract

The United Kingdom is implementing major changes to the national contract for general practitioners (GPs). A central plank of the new arrangements is an ambitious scheme to reward high-quality care. Each general practice will be scored on 146 performance indicators according to the measured quality of care it delivers, and its accumulated score will determine the magnitude of the quality payment it receives. About 18 percent of practice earnings will be at risk. This paper describes the incentive scheme, discusses its potential benefits and risks, and draws out the implications for evaluation.

Mesh:

Year:  2004        PMID: 15160809     DOI: 10.1377/hlthaff.23.3.112

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  15 in total

1.  Do the Quality and Outcomes Framework patient experience indicators reward practices that offer improved access?

Authors:  Richard Baker; M John Bankart; Ged M Murtagh
Journal:  Br J Gen Pract       Date:  2009-06-15       Impact factor: 5.386

2.  The relationship between prescribing expenditure and quality in primary care: an observational study.

Authors:  Robert Fleetcroft; Richard Cookson
Journal:  Br J Gen Pract       Date:  2006-08       Impact factor: 5.386

3.  Better primary physician services lead to fewer hospital admissions.

Authors:  Fredrik Carlsen; Jostein Grytten; Julie Kjelvik; Irene Skau
Journal:  Eur J Health Econ       Date:  2007-03

4.  Rethinking medical professionalism: the role of information technology and practice innovations.

Authors:  David Mechanic
Journal:  Milbank Q       Date:  2008-06       Impact factor: 4.911

5.  The new general practice contract and reform of primary care in the United kingdom.

Authors:  Stephen Peckham
Journal:  Healthc Policy       Date:  2007-05

6.  Compliance with quality prescribing indicators linked to financial incentives: what about not incentivized indicators?: an observational study.

Authors:  R Fernández Urrusuno; P Pérez Pérez; M C Montero Balosa; C Márquez Calzada; B Pascual de la Pisa
Journal:  Eur J Clin Pharmacol       Date:  2013-12-03       Impact factor: 2.953

Review 7.  Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

Authors:  Björn Wettermark; Brian Godman; Karolina Andersson; Lars L Gustafsson; Alan Haycox; Vittorio Bertele
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  Report on financing the new model of family medicine.

Authors:  Stephen J Spann
Journal:  Ann Fam Med       Date:  2004-12-02       Impact factor: 5.166

9.  A 2020 vision of patient-centered primary care.

Authors:  Karen Davis; Stephen C Schoenbaum; Anne-Marie Audet
Journal:  J Gen Intern Med       Date:  2005-10       Impact factor: 5.128

10.  Learning from the European experience of using targets to improve population health.

Authors:  Peter C Smith; Reinhard Busse
Journal:  Prev Chronic Dis       Date:  2010-08-15       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.